This was on the IHUB HALO board, I have not found independent verification, yet, online, but the IHUB poster is quite reliable. Really makes me wonder how many conditions could be improved with Hylenex or PEG.
42 Not yet recruiting Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques Condition: Psoriasis
Interventions: Drug: Hylenex; Drug: Normal Saline
Study Type: Interventional
Phase: Phase 2
Sponsor/Collaborators: University of California, San Diego; Tissa Hata, MD
Funder Type: Other
Study Design: Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Primary Purpose: Treatment; Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Outcome Measures: Physician Global Assessment (PGA); Plaque area; Change in histologic appearance of psoriatic plaques; Change in tumor necrosis factor alpha (TNFa) expression; Change in interferon alpha (IFNa) expression; Change in Toll-like receptor 7 (TLR-7) expression; Change in Toll-like receptor 8 (TLR-8) expression; Change in Toll-like receptor 9 (TLR-9) expression
Number Enrolled: 10
Age Group: Adult
NCT Number: NCT01987609
Other IDs: UCSD 131026
Study Start: January 2014
Primary Completion: October 2014
Study Completion: October 2014
First Received: November 12, 2013
Last Updated: November 18, 2013
Last Verified: November 2013
Results First Received: No Study Results Posted
Int J Tissue React. 1995;17(4):167-73.
Histochemical studies of hyaluronan and the hyaluronan receptor ICAM-1 in psoriasis.
Gustafson S, Wikström T, Juhlin LSourceDepartment of Medical & Physiological Chemistry, University of Uppsala, Sweden.
Psoriasis drug market "to be worth over $7.4B in 2020"
WORLD NEWS | NOVEMBER 22, 2011 58
Sales of drugs to treat psoriasis in seven major markets will increase from a value of $3.9 billion in 2010 to more than $7.4 billion by 2020, according to new forecasts.
This fast growth in the seven markets - the US, France, Germany, Italy, Spain, the UK and Japan - will be due to increases in drug treatment rates and the uptake of key current and emerging therapies, says the study, from Decision Resources.
Market growth will be driven by the continued uptake of Janssen Biotech/Janssen Cilag's Stelara (ustekinumab) and Abbott/Eisai's Humira (adalimumab), plus the launch and prescribing of two emerging therapies - Pfizer's tofacitinib and Novartis' secukinumab, it says.
Abbott withdraws briakinumab applications in USA, Europe
These premium-priced agents are expected to replace less effective existing treatments and drive a rapid increase in sales of therapies for moderate-to-severe disease, which will account for the overwhelming majority of the psoriasis market in 2020, according to the study.